

Serotyping results in 114 ocular toxoplasmosis patients in Germany

	ID	6 I/III	6 d-I/III	6 II	6 d-II	7 II	SAG1
	1	1.2	1.0	1.2	1.1	1.2	13.1
	2	1.2	1.1	1.1	1.2	1.2	9.5
	3	1.0	1.1	1.0	1.3	1.0	9.6
	4	1.0	1.0	1.2	1.1	1.0	2.6
	5	1.1	1.0	1.1	1.2	1.1	2.8
	6	1.0	0.9	1.1	1.0	1.1	18.0
	7	1.1	1.0	1.1	1.1	1.1	9.7
	8	1.2	1.2	1.3	1.2	1.4	14.5
	9	1.1	1.2	1.3	1.3	1.4	14.6
	10	1.1	1.1	1.1	1.4	1.1	13.5
	11	1.2	1.1	1.1	1.1	1.4	23.2
	12	1.0	1.0	1.1	1.0	1.0	4.8
	13	1.2	1.3	1.3	1.2	1.2	13.7
	14	0.9	0.8	1.0	1.1	1.0	9.9
	15	0.8	0.7	0.8	0.7	0.7	2.5
	16	0.9	1.3	1.0	0.9	1.0	6.8
	17	0.7	0.7	0.8	0.7	1.3	17.6
	18	1.0	0.9	1.0	1.0	1.2	2.9
	19	1.1	1.0	1.2	1.1	1.1	16.7
	20	1.1	1.1	1.0	1.2	1.0	7.5
	21	1.3	1.1	1.3	1.2	1.1	21.0
	22	1.1	1.2	1.1	1.0	1.1	21.5
	23	1.0	1.0	1.1	0.9	1.1	11.9
	24	1.2	1.0	0.9	1.2	0.9	7.7
	25	1.2	1.3	1.4	1.0	1.1	3.9
	26	1.3	1.0	1.1	1.0	1.1	18.2
	27	1.2	1.1	1.0	1.0	1.1	17.3
	28	1.2	1.2	1.4	1.3	1.2	8.6
	29	1.2	1.1	1.3	1.2	1.4	22.5
	30	1.3	1.2	1.3	1.2	1.0	7.0
	31	1.3	1.2	1.2	1.0	1.2	18.9
	32	1.0	0.9	1.2	0.9	1.0	7.5
	33	1.3	1.3	1.2	1.0	1.3	4.0
	34	1.1	1.2	1.0	1.1	1.2	4.8
	35	0.9	1.0	0.9	0.9	0.9	13.7
	36	1.0	1.0	1.0	0.9	1.1	5.9
	37	0.9	0.7	0.9	0.8	1.3	14.6
	38	1.1	1.2	1.0	1.1	1.2	20.2
	39	1.0	0.9	1.3	1.2	1.3	16.5
	40	0.7	0.8	0.7	0.7	0.9	5.3
	41	1.2	0.9	1.0	1.0	1.3	27.3
	42	1.4	1.5	0.9	1.2	0.9	20.0
	43	0.8	0.9	1.0	1.0	1.0	20.0
	44	0.9	1.1	1.0	1.1	0.9	21.0
	45	1.0	0.9	0.9	1.0	0.9	20.0
	46	0.9	0.9	0.9	1.3	1.7	20.0
	47	0.9	0.8	0.7	1.1	1.0	4.2
	48	1.0	0.9	1.1	1.2	1.1	20.0
	49	1.1	0.9	1.0	1.2	1.2	20.0
	50	1.0	0.9	1.0	1.0	1.3	8.9
	51	1.0	1.1	3.1	3.6	18.8	35.0
	52	1.0	1.3	1.0	1.4	2.1	10.1
	53	1.3	1.3	2.4	1.7	4.1	18.6
	54	1.2	1.2	2.8	1.1	1.7	30.9
	55	1.0	1.0	1.4	1.1	6.6	23.8
	56	1.2	1.1	3.1	2.9	2.5	24.4
	57	0.9	1.1	1.6	1.6	1.5	7.1
	58	1.1	1.1	1.3	1.2	1.9	27.5
	59	1.2	1.1	2.2	1.6	7.0	25.0
	60	1.1	1.2	2.6	2.2	4.8	25.5
	61	1.0	1.1	1.1	0.9	2.9	15.8
	62	1.4	1.1	1.9	1.4	2.1	25.2
	63	0.9	0.9	4.6	2.5	4.2	17.3
	64	1.2	1.0	2.4	2.2	1.4	30.8
	65	1.1	1.1	1.5	1.3	1.9	19.0
	66	1.1	1.0	2.6	2.3	1.5	29.3
	67	1.1	1.0	1.1	1.5	1.8	6.5
	68	1.0	0.9	1.8	1.0	0.9	14.9
	69	0.9	0.9	1.8	1.8	1.9	16.9
	70	1.4	1.2	6.9	6.7	1.3	15.2
	71	0.9	1.0	1.1	1.2	2.4	9.9
	72	1.0	0.9	2.3	0.9	1.8	7.9
	73	0.9	0.9	0.8	0.9	2.1	14.3
	74	1.0	0.9	1.7	1.2	1.9	25.9
	75	1.0	0.9	2.0	2.0	1.1	11.5
	76	1.3	1.4	2.0	1.1	2.4	8.9
	77	1.1	1.4	1.4	1.7	1.6	20.0
	78	1.3	1.1	2.2	2.0	1.3	20.0
	79	1.0	1.0	1.1	1.2	2.7	9.2
	80	1.0	1.2	1.2	1.4	2.3	20.0
	81	1.1	0.9	2.2	1.9	2.5	20.0
	82	0.9	1.1	1.3	1.6	1.8	20.0
	83	0.8	0.9	1.9	1.2	3.2	20.0
	84	1.1	1.0	2.2	2.2	4.1	20.0
	85	0.9	0.9	3.9	3.5	1.6	20.0
	86	1.0	1.1	6.3	5.7	8.0	11.8
	87	1.1	1.1	9.2	6.3	4.4	20.0
	88	1.3	1.2	1.6	1.5	1.3	20.0
	89	0.9	1.3	1.6	1.3	2.3	20.0
	90	0.8	1.0	1.5	1.5	1.0	20.0
	91	1.2	1.3	2.7	1.8	6.0	20.0
	92	1.1	1.1	6.9	6.1	2.8	20.0
	93	0.9	1.1	1.2	1.3	2.5	14.4
	94	1.0	1.2	2.7	3.2	0.9	20.0
	95	1.1	0.9	1.6	2.2	2.8	20.0
	96	1.4	1.3	7.4	8.4	1.5	20.0
	97	1.3	0.9	1.3	1.0	2.9	5.0
	98	1.9	1.3	1.1	0.9	0.7	10.1
	99	3.0	1.0	1.1	1.4	0.9	28.5
	100	4.6	1.1	1.0	1.0	1.0	14.2
	101	8.2	1.3	1.0	1.0	1.0	36.7
	102	3.4	0.9	0.9	1.0	1.2	24.6
	103	2.2	1.2	1.3	0.9	0.9	21.6
	104	2.2	1.1	1.2	0.9	1.0	16.0
	105	1.6	1.0	1.2	1.0	1.0	24.4
	106	6.1	1.0	1.2	1.1	2.2	34.1
	107	1.6	1.7	1.4	1.3	1.7	10.9
	108	1.6	1.2	1.1	1.2	1.6	20.0
	109	5.8	0.6	0.7	0.9	1.9	20.0
	110	2.8	1.1	4.5	2.1	5.1	20.0
	111	1.5	1.0	2.8	2.6	3.6	14.4
	112	14.8	1.1	7.2	1.1	4.6	20.0
	113	1.8	2.3	4.2	3.3	20.0	20.0
	114	1.5	1.4	1.7	2.0	1.5	11.2

44%

41%

8%

Supplemental Table 1_Shobab et. al.

Non Reactive (NR)
Type II
Atypical I or III

7%